辛伐他汀联合参附注射液治疗合并糖尿病的急性心肌梗死患者心力衰竭临床研究

发布时间：2018-02-10 06:27

本文关键词： 糖尿病急性心肌梗死心力衰竭辛伐他汀参附注射液　出处：《辽宁中医杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的:研究并探讨辛伐他汀联合参附注射液治疗合并糖尿病的急性心肌梗死患者心力衰竭的临床疗效。方法:于2012年6月—2014年2月,选取该阶段内本院收治的88例合并糖尿病的急性心肌梗死患者作为此次研究的对象,采取数字随机表法将患者随机分为对比组和实验组,每组44例。对比组采取常规治疗,实验组在常规治疗的基础上加用参附注射液。比较两组患者的血脂水平、左心功能、炎性标志物水平、药物不良反应、远期生存率。结果:治疗后,实验组的总胆固醇、甘油三酯以及低密度脂蛋白胆固醇均较对比组更低(P0.05),实验组的BNP以及超敏C反应蛋白均较对比组明显更低(P0.05)。与治疗前相比,治疗后两组患者的左室间隔厚度、左心后壁厚度、左室舒张末期内径以及左室射血分数均明显改善(P0.05),且两组之间比较,差异均具有统计学意义(P0.05)。两组患者均未出现明显的不良反应。随访2年发现,实验组的2年生存率为95.45%,较对比组更高。结论:在合并糖尿病且出现心力衰竭的急性心肌梗死患者治疗过程中,给予患者辛伐他汀联合参附注射液治疗,可有效降低患者机体内的血脂水平以及炎性反应,还可有效改善患者的左心功能,提高远期生存率,且安全可靠。
[Abstract]:Objective: To study the clinical curative effect of heart failure in patients with acute myocardial infarction and simvastatin combined with Shenfu Injection in the treatment of diabetes mellitus. Methods: from June 2012 to February 2014, 88 cases of patients with acute myocardial infarction complicated with diabetes from the stage of the hospital as the research object, take the digital random table method were randomly divided into the contrast group and the experimental group, 44 cases in each group. The contrast group was treated with conventional therapy, the experimental group on the basis of conventional treatment combined with Shenfu injection. Comparing the two groups of patients with blood lipid levels, left ventricular function, inflammatory markers, adverse drug reactions, the long-term survival rate. Results: after treatment, the total cholesterol of the experimental group, triglyceride and low density lipoprotein cholesterol were lower compared with the control group (P0.05), experimental group BNP and high sensitive C reactive protein were significantly lower compared with the control group (P0.05) before and after treatment. Compared with left ventricular septal thickness of two groups of patients after treatment, left ventricular posterior wall thickness, left ventricular end diastolic diameter and left ventricular ejection fraction (P0.05) were significantly improved, and the comparison between the two groups, the differences were statistically significant (P0.05). There were no obvious adverse reactions in two groups. 2 years of follow-up, the experimental group 2 years survival rate was 95.45%, compared with the control group higher. Conclusion: in the treatment of acute myocardial infarction patients with diabetes and heart failure process in patients were given simvastatin combined with Shenfu injection treatment, can effectively reduce the blood lipid level in patients with body and inflammatory reaction, but also effectively the improvement of left ventricular function of patients, improve the long-term survival rate, and it is safe and reliable.

【作者单位】：承德医学院附属医院心内科;
【基金】：承德市科技攻关计划项目(200621014)
【分类号】：R542.22;R587.1;R541.6

【参考文献】